ETF Holdings Breakdown of IMNM

Stock Name	Immunome Inc
Ticker	IMNM(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US45257U1088

IMNM institutional holdings

The adjusted close for IMNM on 2025-11-13 was 16.51

The following institutional investment holdings of IMNM have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-13 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 42,381 USD 699,710 16.51

2025-11-13 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 48,873 USD 806,893 16.51

2025-11-13 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 902 USD 14,892 16.51

Total = 92,156 USD 1,521,495
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-13	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	42,381	USD 699,710	16.51
2025-11-13	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	48,873	USD 806,893	16.51
2025-11-13	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	902	USD 14,892	16.51
Total =	92,156	USD 1,521,495

News associated with IMNM

Analysts Set Immunome, Inc. (NASDAQ:IMNM) PT at $22.50: Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned an average rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the […] - 2025-09-05 02:36:50
Guggenheim Reaffirms Buy Rating for Immunome (NASDAQ:IMNM): Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a report issued on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. Guggenheim’s price target indicates a potential upside of 146.06% from the company’s previous close. A number of other equities analysts have […] - 2025-08-27 02:08:53
Wedbush Comments on Immunome’s Q3 Earnings (NASDAQ:IMNM): Immunome, Inc. (NASDAQ:IMNM – Free Report) – Equities research analysts at Wedbush reduced their Q3 2025 earnings per share (EPS) estimates for Immunome in a report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.50) for the quarter, down from their previous forecast […] - 2025-08-12 03:02:57
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Alps Advisors Inc.: Alps Advisors Inc. increased its holdings in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 23.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 62,544 shares of the company’s stock after buying an additional 12,074 shares during the period. Alps Advisors Inc. owned about 0.07% of Immunome […] - 2025-07-15 06:26:33
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Analysts: Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in […] - 2025-06-24 02:52:58
Two Sigma Investments LP Makes New Investment in Immunome, Inc. (NASDAQ:IMNM): Two Sigma Investments LP bought a new stake in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 154,467 shares of the company’s stock, valued at approximately $1,640,000. A number of other institutional investors […] - 2025-06-03 06:04:56
Voya Investment Management LLC Sells 1,439 Shares of Immunome, Inc. (NASDAQ:IMNM): Voya Investment Management LLC cut its holdings in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 8.4% in the 4th quarter, HoldingsChannel reports. The fund owned 15,600 shares of the company’s stock after selling 1,439 shares during the period. Voya Investment Management LLC’s holdings in Immunome were worth $166,000 as of its most recent […] - 2025-05-15 04:49:04
Immunome (NASDAQ:IMNM) Shares Gap Up After Strong Earnings: Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s share price gapped up prior to trading on Tuesday following a stronger than expected earnings report. The stock had previously closed at $7.94, but opened at $8.37. Immunome shares last traded at $8.06, with a volume of 74,171 shares. The company reported ($0.52) earnings per share (EPS) for […] - 2025-05-15 02:18:50
MetLife Investment Management LLC Purchases 5,354 Shares of Immunome, Inc. (NASDAQ:IMNM): MetLife Investment Management LLC increased its holdings in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 17.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 35,619 shares of the company’s stock after acquiring an additional 5,354 shares during the quarter. MetLife Investment Management LLC’s holdings in Immunome were worth $378,000 at the […] - 2025-05-07 06:00:48
Barclays PLC Sells 1,572 Shares of Immunome, Inc. (NASDAQ:IMNM): Barclays PLC decreased its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 104,314 shares of the company’s stock after selling 1,572 shares during the quarter. Barclays PLC’s holdings in Immunome were worth $1,107,000 at the end of the most recent reporting period. […] - 2025-05-05 05:26:54
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.33: Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has received an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in […] - 2025-05-05 03:14:50
Renaissance Technologies LLC Purchases 304,700 Shares of Immunome, Inc. (NASDAQ:IMNM): Renaissance Technologies LLC increased its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 2,696.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 316,000 shares of the company’s stock after acquiring an additional 304,700 shares during the […] - 2025-04-24 04:50:55
JPMorgan Chase & Co. Has $6.89 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM): JPMorgan Chase & Co. raised its holdings in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 2,540.4% in the 4th quarter, HoldingsChannel reports. The fund owned 648,610 shares of the company’s stock after acquiring an additional 624,045 shares during the period. JPMorgan Chase & Co.’s holdings in Immunome were worth $6,888,000 at the end of the […] - 2025-04-17 04:27:20
Corient Private Wealth LLC Sells 12,149 Shares of Immunome, Inc. (NASDAQ:IMNM): Corient Private Wealth LLC trimmed its position in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 50.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 12,085 shares of the company’s stock after selling 12,149 shares during the period. Corient Private Wealth LLC’s holdings in Immunome were worth […] - 2025-04-02 04:22:52
Immunome, Inc. (NASDAQ:IMNM) Holdings Increased by Intech Investment Management LLC: Intech Investment Management LLC increased its stake in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 26.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,961 shares of the company’s stock after acquiring an additional 3,974 shares during the period. Intech […] - 2025-03-27 06:03:10
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Sequoia Financial Advisors LLC: Sequoia Financial Advisors LLC grew its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 11.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 19,065 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Immunome were worth $202,000 as of its […] - 2025-03-21 06:24:53
AlphaQuest LLC Raises Stock Position in Immunome, Inc. (NASDAQ:IMNM): AlphaQuest LLC grew its stake in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 786,700.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,868 shares of the company’s stock after acquiring an additional 7,867 shares during the […] - 2025-03-19 06:20:57
Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital: Investment analysts at Lifesci Capital assumed coverage on shares of Immunome (NASDAQ:IMNM – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $20.00 price target on the stock. Lifesci Capital’s price objective suggests a potential upside of 117.16% from the company’s current […] - 2025-03-13 05:08:48
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity: Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s stock price gapped up prior to trading on Tuesday following insider buying activity. The stock had previously closed at $10.32, but opened at $11.16. Immunome shares last traded at $10.87, with a volume of 472,104 shares trading hands. Specifically, CEO Clay B. Siegall purchased 150,000 shares of the […] - 2025-02-06 04:10:43

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.